Skip to main content

Moderna posts surprise quarterly profit despite waning demand for Covid vaccines

Moderna maintained its full-year guidance of around $5 billion in revenue from its Covid vaccine, its only marketable product.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.